Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $20.9152W HIGH $42.20
Volume
1.67 M
Value Traded
25.20 M
Short % Float
20.54%
-8.36%Week
-6.71%1 Month
-39.71%3 Month
-38.84%6 Month
+265.36%5 Year
+229.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.54 B
EPS (TTM)
-2.17
P/E Ratio
-
Ent. Value
1.86 B
Total Shares
119.49 M
Float Shares
76.26 M
Insiders
36.21%
Institutions
69.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NAMS Catalyst Timeline
Dated clinical, regulatory and corporate events for NewAmsterdam Pharma Company N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NewAmsterdam Pharma Company N.V.
264Total events
12Upcoming
69Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Grant / FundingCorporate
Compensation Committee approved inducement stock option grant of 71,800 shares to 7 new hires
▲First Patient DosedObicetrapibFiledTrial
First participant dosed in Phase 2b SPINOZA trial of obicetrapib in preclinical Alzheimer's disease
preclinical Alzheimer's diseasesource ↗
▲EU ApprovalObicetrapibFiledEx-US Regulatory
Comisión Europea aprueba Evlarco (combinación fija obicetrapib 10 mg + ezetimiba 10 mg)
hipercolesterolemia primaria (HeFH y dislipidemia no familiar o mixta)source ↗
▲EU ApprovalUbesloApprovedEx-US Regulatory
European Commission grants marketing authorization for Ubeslo (obicetrapib monotherapy)
hypercholesterolemia (heterozygous familial hypercholesterolemia and non-familial/mixed dyslipidemia)source ↗
▲EU ApprovalEvlarcoApprovedEx-US Regulatory
European Commission grants marketing authorization for Evlarco (fixed-dose obicetrapib + ezetimibe)
hypercholesterolemia (heterozygous familial hypercholesterolemia and non-familial/mixed dyslipidemia)source ↗
▲EU ApprovalUbesloApprovedEx-US Regulatory
EC grants marketing authorization for Ubeslo (obicetrapib monotherapy)
primary hypercholesterolaemia, both heterozygous familial (HeFH) and non-familial or mixed dyslipidaemiasource ↗
▲EU ApprovalEvlarcoApprovedEx-US Regulatory
EC grants marketing authorization for Evlarco (obicetrapib plus ezetimibe FDC)
primary hypercholesterolaemia, both heterozygous familial (HeFH) and non-familial or mixed dyslipidaemiasource ↗
◆Poster PresentationObicetrapibFiledPresentation
Pooled On-Treatment Lipid-Lowering Efficacy of the CETP Inhibitor Obicetrapib in Phase III Trials
elevated LDL-Csource ↗
◆Poster PresentationObicetrapibFiledPresentation
Determinants of Short Term Lp(a) Variability in Phase 3 Obicetrapib Trials
elevated LDL-Csource ↗
▲CHMP Positive OpinionUbesloApprovedEx-US Regulatory
CHMP positive opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy)
primary hypercholesterolemia (heterozygous familial and non-familial or mixed dyslipidemia)source ↗
▲CHMP Positive OpinionEvlarcoApprovedEx-US Regulatory
CHMP positive opinion recommending marketing authorization for Evlarco (obicetrapib/ezetimibe fixed-dose combination)
primary hypercholesterolemia (heterozygous familial and non-familial or mixed dyslipidemia)source ↗
▲CHMP Positive OpinionUbesloApprovedEx-US Regulatory
Positive CHMP opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy)
primary hypercholesterolemia, both heterozygous familial and non-familial or mixed dyslipidemiasource ↗
▲CHMP Positive OpinionEvlarcoApprovedEx-US Regulatory
Positive CHMP opinion recommending marketing authorization for Evlarco (obicetrapib/ezetimibe fixed-dose combination)
primary hypercholesterolemia, both heterozygous familial and non-familial or mixed dyslipidemiasource ↗
◆EU ApprovalObicetrapibFiledEx-US Regulatory
Decisions on regulatory approval from EMA for obicetrapib and obicetrapib/ezetimibe FDC expected in 2H26
cardiovascular diseasesource ↗
◆Other Regulator MilestoneObicetrapibFiledEx-US Regulatory
Decisions on regulatory approval from UK and Switzerland for obicetrapib and obicetrapib/ezetimibe FDC expected in 2H26
cardiovascular diseasesource ↗
▲CHMP Positive OpinionObicetrapibFiledEx-US Regulatory
CHMP positive opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe
primary hypercholesterolemia or mixed dyslipidemiasource ↗
▲Oral PresentationObicetrapibFiledPresentation
Presented four analyses from BROADWAY at AAIC 2026
Alzheimer's diseasesource ↗
◆Poster PresentationObicetrapibFiledPresentation
CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results From the BROADWAY Trial
hypercholesterolemiasource ↗
◆Poster PresentationPresentation
Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles
hypercholesterolemiasource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
▲Oral PresentationObicetrapibFiledPresentation
Presented four analyses at NLA Scientific Sessions
ASCVD and HeFHsource ↗
◆Oral PresentationPresentation
Virtual fireside chat at 25th Annual Needham Virtual Healthcare Conference
◆EU ApprovalObicetrapibFiledEx-US Regulatory
Approval decision from EMA expected for obicetrapib
cardiovascular diseasesource ↗
◆EU ApprovalObicetrapibFiledEx-US Regulatory
EMA approval decision for obicetrapib/ezetimibe FDC expected
cardiovascular diseasesource ↗
◆Other Regulator MilestoneObicetrapibFiledEx-US Regulatory
Approval decision from Switzerland regulator expected for obicetrapib
cardiovascular diseasesource ↗
◆EU ApprovalObicetrapibFiledEx-US Regulatory
Approval decision from EMA expected for obicetrapib/ezetimibe FDC
cardiovascular diseasesource ↗
◆Other Regulator MilestoneObicetrapibFiledEx-US Regulatory
Approval decision from Switzerland regulator expected for obicetrapib/ezetimibe FDC
cardiovascular diseasesource ↗
◆Timing GuidanceUbesloApprovedPresentation
European Commission decision on marketing authorization for Ubeslo (obicetrapib monotherapy)
primary hypercholesterolemia (heterozygous familial and non-familial or mixed dyslipidemia)source ↗
◆Timing GuidanceEvlarcoApprovedPresentation
European Commission decision on marketing authorization for Evlarco (obicetrapib/ezetimibe fixed-dose combination)
primary hypercholesterolemia (heterozygous familial and non-familial or mixed dyslipidemia)source ↗
◆Poster PresentationPresentation
Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles
cardiovascular diseasesource ↗
◆Poster PresentationObicetrapibFiledPresentation
Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis
hypercholesterolemiasource ↗
◆Poster PresentationObicetrapibFiledPresentation
CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial
hypercholesterolemiasource ↗
◆Oral PresentationPresentation
Company management to participate in upcoming investor conferences in March
▲Enrollment CompleteObicetrapibFiledTrial
REMBRANDT completed enrollment of 323 patients
ASCVDsource ↗
●Oral PresentationObicetrapibFiledPresentation
Presented new analyses of Phase 3 BROOKLYN and BROADWAY at ACC in March 2026
ASCVD and/or HeFHsource ↗
●PublicationObicetrapibFiledPresentation
Simultaneously published in American Journal of Preventative Cardiology in March 2026
ASCVD and/or HeFHsource ↗
◆Oral PresentationPresentation
Virtual fireside chat at Guggenheim Emerging Outlook: Biotech Summit
▲Product LaunchObicetrapibFiledPost-Market
Potential global launch of obicetrapib
hypercholesterolemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How NAMS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-12 | Obicetrapib | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$1.2B
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.4x
rNPV / MCap
Top 16%
Small Cap(rank 106 of 658)
Percentile Rank
NewAmsterdam Pharma Company N.V. carries a moderate pipeline score (51/100), with $1.8B risk-adjusted pipeline value, led by Obicetrapib in Atherosclerotic Cardiovascular Disease (Phase 3), across $66B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Obicetrapib Small moleculeNCT05202509 | Atherosclerotic Cardiovascular Disease | Phase 3 | ACTIVE NOT_RECRUITING | 9,541 | Nov 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every NAMS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kastelein Johannes Jacob PieterDirector, Officer (Chief Scientific Officer) | Option | 50,246 119,548 held | $0.00 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NAMS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 13.3 % (-5 %) | 613.03 M | 18.09 M | 6.76% ( 1.15 M) |
NAMS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NAMS ranks across every disease it competes in
Competitive Position is a premium feature
See how NAMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNAMS News
NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma has announced the approval of inducement share options and restricted stock units for new non-executive hires. A total of 71,800 share options and 17,745 restricted stock units were granted under the 2024 Inducement Plan. These grants aim to incentivize new employees and align their interests with the company's growth.
Read more →NAMSNewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
NewAmsterdam Pharma has initiated the SPINOZA trial, dosing its first participant to evaluate obicetrapib in individuals with preclinical Alzheimer's disease. This Phase 2b trial aims to assess the drug's impact on biomarkers associated with Alzheimer's pathology. The study will involve approximately 400 participants and is designed to explore the efficacy and safety of obicetrapib before clinical symptoms manifest.
Read more →NAMSMenarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
Menarini Group and NewAmsterdam Pharma have received European Commission approval for Ubeslo® and Evlarco®, marking the first global regulatory approval for obicetrapib. This approval is based on phase 3 trials showing significant reductions in LDL-C levels. The drugs offer new treatment options for patients with primary hypercholesterolemia.
Read more →NAMSMenarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo® (Obicetrapib als Monotherapie) und Evlarco® (Fixkombination aus Obicetrapib und Ezetimib)
NewAmsterdam Pharma and Menarini Group have received approval from the European Commission for Ubeslo (Obicetrapib as monotherapy) and Evlarco (combination of Obicetrapib and Ezetimib). This marks the first global approval of Obicetrapib, providing a new treatment option for patients with primary hypercholesterolemia. The approval is based on positive results from Phase 3 studies demonstrating significant LDL-C reductions.
Read more →NAMSMenarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma and Menarini Group have received European Commission approval for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe). This marks the first global regulatory approval for obicetrapib, supported by positive results from Phase 3 trials showing significant reductions in LDL-C levels. The approval aims to provide new treatment options for patients struggling with elevated LDL-C.
Read more →NAMSNewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma and Menarini Group have received European Commission approval for Ubeslo® and Evlarco®, marking the first global regulatory approval for obicetrapib. This approval is supported by Phase 3 trials showing significant reductions in LDL-C levels. The companies aim to provide new treatment options for patients struggling with elevated LDL-C levels.
Read more →NAMSNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
NewAmsterdam Pharma will participate in two investor conferences in September 2026, showcasing its commitment to addressing cardiovascular disease. CEO Michael Davidson and EVP Matthew Philippe will present at the Wells Fargo Healthcare Conference, while CFO Ian Somaiya will join the Cantor Global Healthcare Conference. Live webcasts of the events will be available on their website.
Read more →NAMSNewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
NewAmsterdam Pharma will present findings from its obicetrapib development program at the ESC Congress 2026 in Munich. The presentations will cover various aspects of obicetrapib's efficacy and safety in lowering LDL cholesterol. The company aims to address unmet needs in cardiovascular disease treatment with this novel therapy. The Phase 3 PREVAIL trial has successfully enrolled over 9,500 patients.
Read more →NAMSNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
NewAmsterdam Pharma reported a positive opinion from the CHMP recommending marketing authorization for obicetrapib and its combination with ezetimibe. The company announced a strong cash position of $678.3 million and highlighted upcoming clinical milestones, including topline data from the RUBENS Phase 3 trial expected by the end of 2026. However, the company also reported a net loss of $64.1 million for the quarter, reflecting increased R&D expenses.
Read more →NAMSNewAmsterdam Pharma to Host Investor Day on August 5, 2026
NewAmsterdam Pharma will host an Investor Day on August 5, 2026, in New York City. The event will feature key executives and provide insights into the company's developments, particularly regarding obicetrapib, a novel treatment for cardiovascular disease. A live webcast will be available for those unable to attend in person.
Read more →NAMSNewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)
NewAmsterdam Pharma and Menarini Group received a positive CHMP recommendation for the approval of Ubeslo® (Obicetrapib monotherapy) and Evlarco® (combination with Ezetimib). This recommendation is based on favorable Phase 3 study results showing significant LDL-C reductions. The final decision from the European Commission is expected in the second half of 2026.
Read more →NAMSNewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo®
NewAmsterdam Pharma and Menarini Group received a positive opinion from the CHMP recommending the marketing authorization of Ubeslo® and Evlarco®. This recommendation is based on favorable results from phase 3 trials, indicating significant LDL-C reduction. The final decision from the European Commission is expected in the second half of 2026.
Read more →NAMSNewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma and Menarini Group received a positive opinion from the CHMP recommending marketing authorization for obicetrapib monotherapy and its fixed-dose combination with ezetimibe. This recommendation is based on positive results from Phase 3 trials, indicating significant LDL-C reductions. The European Commission's final decision is anticipated in the second half of 2026.
Read more →NAMSNewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
NewAmsterdam Pharma announced it will present data on obicetrapib at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will focus on the drug's potential in preventing early Alzheimer's disease, supported by findings from the BROADWAY trial. The company aims to address unmet needs in cardiovascular disease management with this novel therapy.
Read more →NAMSNewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
NewAmsterdam Pharma announced its upcoming presentations at the National Lipid Association 2026 Scientific Sessions, focusing on obicetrapib, a novel oral therapy for hypercholesterolemia. The presentations will cover various aspects of obicetrapib, including safety analyses and its effects on LDL cholesterol. The event will take place from June 11 to 14, 2026, in Chicago.
Read more →NAMSNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma will participate in two major investor conferences in June 2026. CEO Michael Davidson and EVP Matthew Philippe will engage in fireside chats at the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. These events will provide insights into the company's developments in LDL-lowering therapies for cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NewAmsterdam Pharma will participate in two upcoming investor conferences in May 2026. The BofA Securities Health Care Conference will take place on May 12, followed by the RBCCM Global Healthcare Conference on May 20. Key executives will engage in fireside chats, discussing the company's innovative approaches to treating cardiovascular disease.
Read more →About NewAmsterdam Pharma Company N.V.
HeadquartersGOOIMEER 2-35, NARRDEN, P7, 1411 DC
BIOPHARMAWATCH ELITE PLUS
Trade the next NAMS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime